Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure.
Fiche du document
2010
- doi: 10.1086/655779
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1086/655779
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/20726764
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1537-6613[electronic], 0022-1899[linking]
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_C78C1D7C098E7
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Ague Chills and fever Intermittent fever Malarial feverCiter ce document
Maria Hodel Eva et al., « Residual antimalarial concentrations before treatment in patients with malaria from Cambodia: indication of drug pressure. », Serveur académique Lausannois, ID : 10.1086/655779
Métriques
Partage / Export
Résumé
BACKGROUND: The Thai-Cambodian border has been known as the origin of antimalarial drug resistance for the past 30 years. There is a highly diverse market for antimalarials in this area, and improved knowledge of drug pressure would be useful to target interventions aimed at reducing inappropriate drug use. METHODS: Baseline samples from 125 patients with falciparum malaria recruited for 2 in vivo studies (in Preah Vihear and Pursat provinces) were analyzed for the presence of 14 antimalarials in a single run, by means of a liquid chromatography-tandem mass spectrometry assay. RESULTS: Half of the patients had residual drug concentrations above the lower limit of calibration for at least 1 antimalarial at admission. Among the drugs detected were the currently used first-line drugs mefloquine (25% and 35% of patients) and piperaquine (15% of patients); the first-line drug against vivax malaria, chloroquine (25% and 41% of patients); and the former first-line drug, quinine (5% and 34% patients). CONCLUSIONS: The findings demonstrate that there is high drug pressure and that many people still seek treatment in the private and informal sector, where appropriate treatment is not guaranteed. Promotion of comprehensive behavioral change, communication, community-based mobilization, and advocacy are vital to contain the emergence and spread of parasite resistance against new antimalarials.